The origins of bladder cancer

Laboratory Investigation

Volumn 88, Issue 7, 2008, Pages 686-693

  Crawford, James M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder cancer; Forerunner genes; Genomic mapping; P2RY5; RB1; Whole organ mapping

Indexed keywords

ARSENIC;

BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER WALL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER MODEL; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CELL CLONE; CELL DIVISION; CELL EXPANSION; CHROMOSOME; CYSTOSCOPY; DYSPLASIA; FAMILIAL CANCER; GENE CLUSTER; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; INTRON; METASTASIS; MUCOSA; MUTATION; NONHUMAN; OCCUPATIONAL EXPOSURE; POPULATION GENETIC PARAMETERS; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SMOKING; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; URINE CYTOLOGY; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 46049114088     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.48     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. Br J Urol 2007;101:11-19.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
4. Knowles MA. The genetics of transitional cell carcinoma: progress and potential clinical application. Brit J Urol Int 1999;84:412-427.
5. Speiss PE, Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 2006;130:844-852.
6. Malkowicz SB, Van Poppel H, Mickisch G, et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007;69(Suppl 1):3-16.
7. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24:296-304.
8. Hermann GG, Horn T, Steven K, et al. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91-94.
9. Dinney CP, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-116.
10. Clavel J. Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer. C R Biol 2007;330:306-317.
11. Tang L, Zirpoli GR, Guru K, et al. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:938-944.
12. Pelucchi C, Bosetti C, Negri E, et al. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006;3:327-340.
13. Silverman DT, Devesa SS, Moore LE, et al. Bladder cancer. In: Schottenfeld D, Fraumeni JF (eds). Cancer Epidemiol Prev. Oxford University Press: Oxford, 2006, pp 1101-1127.
14. Jee SH, Samet JM, Ohrr H, et al. Smoking and cancer risk in Korean men and women. Cancer Causes Control 2004;15:341-348.
15. Gritz ER, Dresler C, Sarna L, et al. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287-2293.
16. Zeegers MP, Goldbohm RA, van den Brandt PA. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 2002;13:83-90.
17. Marsit CJ, Houseman EA, Schned AR, et al. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007;28:1745-1751.
18. Ye Y, Yang H, Grossman HB, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, published online 24 March 2008, PMID 18361427.
19. Gaspari L, Marinelli D, Taioli E, Collaborative Group on Genetic Susceptibility to Environmental Carcinogens. Int J Hyg Environ Health 2001;204:39-42.
20. Jones PA, Gonzalgo ML, Tsutsumi M, et al. DNA methylation in bladder cancer. Eur Urol 1998;33(Suppl 4):7-8.
21. Marsit CJ, Karagas MR, Andrew A, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 2005;65:7081-7085.
22. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;612:8659-8663.
23. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-478.
24. Marsit CJ, Karagas MR, Danaee H, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-116.
25. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000;60:2473-2476.
26. Marsit CJ, Houseman EA, Christensen BC, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006;66:10621-10629.
27. Sanchez B, Budtz-Jørgensen E, Ryan LM, et al. Structural equation models - a review with applications to environmental epidemiology. J Am Stat Assoc 2005;1000:1443-1455.
28. Bartholomew DJ. Latent Variable Models and Factor Analysis. Oxford University Press: New York, 1999.
29. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007;13:2046-2053.
30. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005;26:1481-1487.
31. Lynch H, Walzak M, Fried R, et al. Familial factors in bladder carcinoma. J Urol 1979;122:458-461.
32. Fraumeni Jr JF, Thomas LB. Malignant bladder tumors in a man and his three sons. J Am Med Assoc 1967;201:97-99.
33. Mahboubi A, Ahlvin R, Mahboubi E. Familial aggregation of urothelial carcinoma. J Urol 1981;126:691-692.
34. McCullough DL, Lama DL, McLaughlin AP, et al. Familial transitional cell carcinoma of the bladder. J Urol 1975;113:629-635.
35. Kramer A, Graham S, Burnett W, et al. Familial aggregation of bladder cancer stratified by smoking status. Epidemiology 1991;2:145-148.
36. Aben KKH, Witjes JA, Schoenberg MP, et al. Familial aggregation of urothelial cell carcinoma. In J Cancer 2002;98:274-278.
37. Randi G, Pelucchi C, Negri E, et al. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer 2007;121:2748-2752.
38. Lichtenstein R, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer. Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Eng J Med 2000;343:78-85.
39. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007;25:285-295.
40. Murta-Nascimento C, Silverman DT, Kogevinas M, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007;16:1595-1600.
41. Lin J, Spitz MR, Dinney CP, et al. Bladder cancer risk as modified by family history and smoking. Cancer 2006;107:705-711.
42. Tuziak T, Jeong J, Majewski T, et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest 2005;85:689-701.
43. Kim MS, Jeong J, Majewski T, et al. Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab Invest 2006;86:175-190.
44. Lee S, Jeong J, Majewski T, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci USA 2007;104:13732-13737.
45. Majewski T, Lee S, Jeong J, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest [e-pub ahead of print: advance online publication 5 May 2008].
46. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008;105:4283-4288.
47. Chatelain D, Fléjou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch 2003;442:18-24.
48. Höglund M. Bladder cancer, a two phased disease? Semin Cancer Biol 2007;17:225-232.
49. Tomovska S, Richter J, Suess K, et al. Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer. Int J Oncol 2001;18:1239-1244.
50. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006;66:3434-3442.
51. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-1518.
52. Hurst CD, Fiegler H, Carr P, et al. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004;23:2250-2263.
53. Leone G, Nuckolls F, Ishida S, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 2000;20:3626-3632.
54. Humbert PO, Verona R, Trimarchi JM, et al. E2f3 is critical for normal cellular proliferation. Genes Dev 2000;14:690-703.
55. Lees JA, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13:7813-7825.
56. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005;24:2810-2826.
57. Oeggerli M, Schraml P, Ruiz C, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006;25:6538-6543.
58. Olsson AY, Feber A, Edwards S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007;26:1028-1037.
59. Hurst CD, Tomlinson DC, Williams SV, et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008;27:2716-2727.
60. Hellwinkel OJC, Kedia M, Isbarn H, et al. Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours. Brit J Urol Int 2007;101:753-757.
61. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nature Gen 2008;40:316-321.
62. Suzuki A, Shibata T, Shimada Y, et al. Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization. Cancer Sci 2008;99:986-994.
63. Oldenburg RA, Meijers-Heijboer HM, Cornelisse CJ, et al. Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol/Hematol 2007;63:125-149.
64. Kallioniemi A. CGH microarrays and cancer. Curr Op Biotechnol 2008;19:36-40.
65. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nature Gen 2008;40:310-315.
66. Shann YJ, Cheng C, Chiao CH, et al. Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines. Genome Res 2008; e-pub ahead of print. PMID 18256232.
67. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Gen 2008;40:616-622.
68. Monzon FA, Hagenkord JM, Lyons-Weiler MA, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 2008;21:599-608.
69. Baffa R, Letko J, McClung C, et al. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res 2006;25:145-160.
70. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007;17:341-346.
71. Steiner H, Bergmeister M, Verdorfer I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. Brit J Urol International epub ahead of print. PMID 18336612.
72. Frigerio S, Padberg BC, Strebel RT, et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite status. Int J Cancer 2007;121:329-338.
73. Szarvas T, Kovalszky I, Bedi K, et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol Rep 2007;18:405-409.
74. Bartoletti R, Dal Canto M, Cai T, et al. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 2005;13:531-537.
75. Wakui M, Shiigai T. Urinary tract cancer screening through analysis of urinary red blood cell volume distribution. Int J Urol 2000;7:248-253.
76. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107:2173-2179.
77. Messing EM, Young TB, Hung VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-396.
78. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a caseseries meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000;9:461-467.
79. Miyakawa M, Tachibana M, Miyakawa A, et al. Re-evaluation of the latent period of bladder cancer in dyestuff-plant workers in Japan. Int J Urol 2001;8:423-430.
80. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994;151:21-26.
81. Prout Jr GR, Barton BA. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl 1992;16I:148-152.
82. Decensi A, Bruno S, Costantini M, et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994;86:138-140.
83. Bruno S, Torrisi R, Costantini M, et al. Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 1999;76:311-321.
84. Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995;28:284-290.
85. Sabichi AL, Lerner SP, Atkinson EN, et al. Phase III prevention trial of fenretinide in patients with resected non muscle-invasive bladder cancer. Clin Cancer Res 2008;14:224-229.
86. Messing E, Kim K, Sharkey F, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006;176:500-504.
87. Grossman HB. Chemoprevention of bladder cancer. Urology 2006;67:19-22.